Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Importance: Governments worldwide have become increasingly cognizant of the spread of genetic discrimination (negative treatment or harm on the basis of actual or presumed genetic characteristics). Despite efforts by a number of governments to establish regulations addressing this phenomenon, public concern about genetic discrimination persists.
Objective: To identify key elements of an optimal genetic nondiscrimination policy and inform policymakers as they seek to allay genetic nondiscrimination and related public anxieties.
Evidence Review: Sixty multidisciplinary experts from 20 jurisdictions worldwide were consulted to understand their views on effective genetic nondiscrimination policies. Following standard requirements of the Delphi method, 3 rounds of surveys over the course of 1.5 years were conducted. Round 1 focused on assessing participants' understanding of the intricacies of existing genetic nondiscrimination policies, while rounds 2 and 3 invited participants to reflect on specific means of implementing a more effective regime. A total of 60 respondents participated in the first round, 53 participated in round 2, and 43 participated in round 3.
Findings: While responses varied across disciplines, there was consensus that binding regulations that reach across various sectors are most useful in preventing genetic discrimination. Overall, experts agreed that human rights-based approaches are well suited to preventing genetic discrimination. Experts also agreed that explicit prohibition of genetic discrimination within nondiscrimination policies can highlight the importance of genetic nondiscrimination as a fundamental right and ensure robust protection at a national level. While most participants believed the international harmonization of genetic nondiscrimination laws would facilitate data sharing worldwide, they also recognized that regulations must reflect the sociocultural differences that exist among regions.
Conclusions And Relevance: As the reach of genetic discrimination continues to evolve alongside developments in genomics, strategic policy responses that are harmonious at the international and state levels will be critical to address this phenomenon. In seeking to establish comprehensive frameworks, policymakers will need to be mindful of regional and local circumstances that influence the need for and efficacy of unique genetic nondiscrimination approaches across diverse contexts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamanetworkopen.2024.35355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Shifting ownership, shifting protections: Patient privacy and genetic data ownership in the era of mergers and acquisitions.
J Genet Couns
August 2025
Scripps Research Translational Institute, La Jolla, California, USA.
Genetic data, more than ever, are a sought-after asset, often transferred or repurposed under broad privacy policies with limited transparency and passive consent. With the increasing frequency of company mergers and acquisitions within the genetics and genomics industry, growing and underacknowledged risks to patient data privacy have emerged. Though informed consent is a foundational element of clinical genetics, our current process rarely addresses what happens to patient data during business transitions.
View Article and Find Full Text PDFWorkplace Genomic Testing: What Do Company Websites Say about Federal Privacy and Anti-Discrimination Laws?
Public Health Genomics
June 2025
Department of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Introduction: Employees considering participation in workplace genetic and/or genomic testing (wGT) as part of workplace wellness programs should be aware of legal protections of their personal genetic information. Given the relevance of the Health Insurance Portability and Accountability Act (HIPAA) and the Genetic Information Nondiscrimination Act (GINA) for informed decision-making, employers offering wGT should ideally inform employees of these health policies prior to collecting any genetic data. It is unclear, however, whether and to what extent such information is being provided.
View Article and Find Full Text PDFDual DNA recycling amplification-assisted CRISPR/Cas12a cleavage for dual-channel ratiometric fluorescence biosensing of kanamycin antibiotic.
Anal Bioanal Chem
June 2025
Hubei Key Laboratory of Pollutant Analysis & Reuse Technology, College of Chemistry and Chemical Engineering, Hubei Normal University, Huangshi, 435002, China.
Fluorescence biosensors hold significant importance for testing antibiotic residues which seriously endanger public health. However, how to adopt appropriate strategies to address the false result disadvantage involved in traditional single-channel biosensors is still a great challenge. Meanwhile, too much attention focused on designing signal amplification strategies of biosensors unavoidably decreases their detection efficiency.
View Article and Find Full Text PDFGenetic discrimination in insurance and employment based on personalized risk stratification for breast cancer screening.
Front Genet
March 2025
Centre of Genomics and Policy (CGP), McGill University, Montreal, QC, Canada.
Background: The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) incorporates the effects of common genetic variants, from polygenic risk scores, pathogenic variants in major breast cancer (BC) susceptibility genes, lifestyle/hormonal risk factors, mammographic density, and cancer family history to predict risk levels of developing breast and ovarian cancer. While offering multifactorial risk assessment to the population could be a promising avenue for early detection of BC, obstacles to its implementation including fear of genetic discrimination (GD), could prevent individuals from undergoing screening.
Methods: The aim of our study was two-fold: determine the extent of legal protection in Canada available to protect information generated by risk prediction models such as the BOADICEA algorithm through a literature review, and then, assess individuals' knowledge of and concerns about GD in this context by collecting data through surveys.
A scoping review of human genetic resources management policies and databases in high- and middle-low-income countries.
BMC Med Ethics
March 2025
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Background: This review examines global human genetic resources management, focusing on genetic data policies and repositories in high- and middle-low-income countries.
Methods: A comprehensive search strategy was employed across multiple databases, including official government websites and Google, to gather relevant literature on human genetic resources management policies and genetic resource databases. Documents were screened for relevance, focusing on high-income countries (United States, United Kingdom, Japan) and middle-low-income countries (China, India, Kenya).